drugset

drugset / Trial / NCT00212693

Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan

NCT00212693 ↗

Phase 2 Completed 165 enrolled Ono Pharmaceutical Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of ONO-2506PO in patients with Parkinson's Disease

Timeline

Start: 2004-01
Primary completion: 2005-09
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ARUNDIC ACID	Small molecule	—	—

Indications